Bone Biologics Co. (NASDAQ:BBLG) Sees Large Drop in Short Interest

Bone Biologics Co. (NASDAQ:BBLG) saw a large drop in short interest in August. As of August 31st, there was short interest totalling 12,500 shares, a drop of 31.3% from the August 15th total of 18,200 shares. Approximately 2.4% of the shares of the stock are short sold. Based on an average trading volume of 2,060,000 shares, the days-to-cover ratio is currently 0.0 days.

Bone Biologics Stock Up 136.3 %

BBLG traded up $1.09 during midday trading on Monday, hitting $1.89. 160,929,334 shares of the company were exchanged, compared to its average volume of 1,718,196. Bone Biologics has a 1-year low of $0.80 and a 1-year high of $10.56. The firm’s 50 day moving average price is $1.51 and its 200-day moving average price is $1.68.

Bone Biologics (NASDAQ:BBLG) last announced its earnings results on Friday, August 9th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($1.39) by $0.72. On average, analysts anticipate that Bone Biologics will post -3.17 EPS for the current year.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.